Skip to main content
Erschienen in: Heart Failure Reviews 2/2019

20.10.2018

Chronic heart failure: a disease of the brain

verfasst von: Ram B. Singh, Krasimira Hristova, Jan Fedacko, Galal El-Kilany, Germaine Cornelissen

Erschienen in: Heart Failure Reviews | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. This phenomenon may be the result of an increased systemic and cerebral angiotensin II signaling because plasma angiotensin II is increased in humans and animals with chronic HF. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic HF. Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. It is possible that blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the PVN. The administration of an angiotensin receptor blocker by injection into the AP activates the sympatho-inhibitory baroreflex indicating that receptor blockers act by increasing parasympathetic activity. In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Increased circulating angiotensin II during chronic HF may enhance the sympatho-excitatory chemoreflex and inhibit the sympatho-inhibitory baroreflex resulting in worsening of HF. Increased circulating angiotensin II signaling can directly act on the central nervous system via the subfornical organ and the AP to increase sympathetic outflow resulting in to neurohumoral dysfunction, resulting in to heart failure.
Literatur
1.
Zurück zum Zitat Hristova K, Singh RB, Fedacko J, Toda E, Kumar A, Saxena M, Baby A, Takahashi T, De Meester F, Wilson DW (2013) Causes and risk factors of congestive heart failure in India. World Heart J 5:13–20 Hristova K, Singh RB, Fedacko J, Toda E, Kumar A, Saxena M, Baby A, Takahashi T, De Meester F, Wilson DW (2013) Causes and risk factors of congestive heart failure in India. World Heart J 5:13–20
2.
Zurück zum Zitat Fedacko J, Singh RB, Gupta A, Hristova K, Toda E, Kumar A, Saxena M, Baby A, Singh R, Takahashi T, Wilson DW (2014) Inflammatory mediators in chronic heart failure in North India. Acta Cardiol 69:391–984CrossRefPubMed Fedacko J, Singh RB, Gupta A, Hristova K, Toda E, Kumar A, Saxena M, Baby A, Singh R, Takahashi T, Wilson DW (2014) Inflammatory mediators in chronic heart failure in North India. Acta Cardiol 69:391–984CrossRefPubMed
5.
6.
Zurück zum Zitat Kishi T (2012) Heart failure as an autonomic nervous system dysfunction. J Cardiol 59:117–122CrossRefPubMed Kishi T (2012) Heart failure as an autonomic nervous system dysfunction. J Cardiol 59:117–122CrossRefPubMed
7.
Zurück zum Zitat Floras JS (2009) Sympathetic nervous system activation in heart failure. Clinical implications of an updated model. J Am Coll Cardiol 54:375–385CrossRefPubMed Floras JS (2009) Sympathetic nervous system activation in heart failure. Clinical implications of an updated model. J Am Coll Cardiol 54:375–385CrossRefPubMed
9.
Zurück zum Zitat Witte KKA, Clark AL, Cleland JCF (2001) Chronic heart failure and micronutrients. JACC 37:1765–1774CrossRefPubMed Witte KKA, Clark AL, Cleland JCF (2001) Chronic heart failure and micronutrients. JACC 37:1765–1774CrossRefPubMed
10.
Zurück zum Zitat Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, Mechirova V, Pella D, Chopra R (2007) Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 62:349–354CrossRefPubMed Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, Mechirova V, Pella D, Chopra R (2007) Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 62:349–354CrossRefPubMed
13.
Zurück zum Zitat Zannad F, De Ferrari GM, Tuinenberg AE, Wright D et al (2015) Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the neural cardiac therapy for heart failure (NECTAR-HF), a randomized controlled trial. Eur Heart J 36:425–436 Zannad F, De Ferrari GM, Tuinenberg AE, Wright D et al (2015) Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the neural cardiac therapy for heart failure (NECTAR-HF), a randomized controlled trial. Eur Heart J 36:425–436
14.
Zurück zum Zitat Kubo T, Sato T, Noguchi T, Kitaoka H, Yamasaki F, Kamimura N, Shimodera S, Iiyama T, Kumagai N, Kakinuma Y, Diedrich A, Jordan J, Robertson D, Doi YL (2012) Influences of donepezil on cardiovascular system--possible therapeutic benefits for heart failure--donepezil cardiac test registry (DOCTER) study. J Cardiovasc Pharmacol 60:310–314CrossRefPubMed Kubo T, Sato T, Noguchi T, Kitaoka H, Yamasaki F, Kamimura N, Shimodera S, Iiyama T, Kumagai N, Kakinuma Y, Diedrich A, Jordan J, Robertson D, Doi YL (2012) Influences of donepezil on cardiovascular system--possible therapeutic benefits for heart failure--donepezil cardiac test registry (DOCTER) study. J Cardiovasc Pharmacol 60:310–314CrossRefPubMed
15.
Zurück zum Zitat Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M (2013) The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s disease. Eur Heart J 34:2585–2591CrossRefPubMed Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M (2013) The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s disease. Eur Heart J 34:2585–2591CrossRefPubMed
19.
Zurück zum Zitat McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg, Zile MR, for the PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg, Zile MR, for the PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed
20.
Zurück zum Zitat Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR (2001) Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol 52:159–164CrossRefPubMedPubMedCentral Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR (2001) Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol 52:159–164CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Dai J, Lampert R, Wilson PW, Goldberg J, Ziegler TR, Vaccarino V (2010) Mediterranean dietary pattern is associated with improved cardiac autonomic function among middle-aged men: a twin study. Circ Cardiovasc Qual Outcomes 3(4):366–373CrossRefPubMedPubMedCentral Dai J, Lampert R, Wilson PW, Goldberg J, Ziegler TR, Vaccarino V (2010) Mediterranean dietary pattern is associated with improved cardiac autonomic function among middle-aged men: a twin study. Circ Cardiovasc Qual Outcomes 3(4):366–373CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Gal D, Pella D, Singh RB (2008) The effect of an alpha-linolenic acid rich diet on the circadian rhythm of cardiac events. World Heart J 1:49–56 Gal D, Pella D, Singh RB (2008) The effect of an alpha-linolenic acid rich diet on the circadian rhythm of cardiac events. World Heart J 1:49–56
23.
Zurück zum Zitat Singh RB, Hristova K, El-Kilany G, Takahashi T, Shehab A, Chaves H, Wilson DW, Rupini D, Gupta N, Gupta R (2015) Nutritional modulators of chronic heart failure. Open Nutra J 8:1–4CrossRef Singh RB, Hristova K, El-Kilany G, Takahashi T, Shehab A, Chaves H, Wilson DW, Rupini D, Gupta N, Gupta R (2015) Nutritional modulators of chronic heart failure. Open Nutra J 8:1–4CrossRef
24.
Zurück zum Zitat Watanabe E, Arakawa T, Uchiyama T, Tong M, Yasui K, Takeuchi H, Terasawa T, Kodama I, Hishida H (2007) Prognostic significance of circadian variability of RR and QT intervals and QT dynamicity in patients with chronic heart failure. Heart Rhythm 4(8):999–1005CrossRefPubMed Watanabe E, Arakawa T, Uchiyama T, Tong M, Yasui K, Takeuchi H, Terasawa T, Kodama I, Hishida H (2007) Prognostic significance of circadian variability of RR and QT intervals and QT dynamicity in patients with chronic heart failure. Heart Rhythm 4(8):999–1005CrossRefPubMed
25.
Zurück zum Zitat Kim SG, Yum MK (2000) Decreased RR interval complexity and loss of circadian rhythm in patients with congestive heart failure. Jpn Circ J 64(1):39–45CrossRefPubMed Kim SG, Yum MK (2000) Decreased RR interval complexity and loss of circadian rhythm in patients with congestive heart failure. Jpn Circ J 64(1):39–45CrossRefPubMed
26.
Zurück zum Zitat Yamazaki T, Asanoi H, Ueno H, Yamada K, Takagawa J, Kameyama T, Hirai T, Nozawa T, Inoue H (2005) Circadian dynamics of heart rate and physical activity in patients with heart failure. Clin Exp Hypertens (New York) 27(2–3):241–249 Yamazaki T, Asanoi H, Ueno H, Yamada K, Takagawa J, Kameyama T, Hirai T, Nozawa T, Inoue H (2005) Circadian dynamics of heart rate and physical activity in patients with heart failure. Clin Exp Hypertens (New York) 27(2–3):241–249
27.
Zurück zum Zitat Carson PA, O’Connor CM, Miller AB, Anderson S, Belkin R, Neuberg GW, Wertheimer JH, Frid D, Cropp A, Packer M (2000) Circadian rhythm and sudden death in heart failure: results from prospective randomized amlodipine survival trial. J Am Coll Cardiol 36(2):541–546CrossRefPubMed Carson PA, O’Connor CM, Miller AB, Anderson S, Belkin R, Neuberg GW, Wertheimer JH, Frid D, Cropp A, Packer M (2000) Circadian rhythm and sudden death in heart failure: results from prospective randomized amlodipine survival trial. J Am Coll Cardiol 36(2):541–546CrossRefPubMed
28.
Zurück zum Zitat Yee KM, Pringle SD, Struthers AD (2001) Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37:1800–1807CrossRefPubMed Yee KM, Pringle SD, Struthers AD (2001) Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37:1800–1807CrossRefPubMed
29.
Zurück zum Zitat Dzida G, Prystupa A, Lachowska-Kotowska P, Kadas T, Kamienski P, Kimak E, Halabis M, Kicinski P (2013) Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure. Ann Agric Environ Med 20(4):745–748PubMed Dzida G, Prystupa A, Lachowska-Kotowska P, Kadas T, Kamienski P, Kimak E, Halabis M, Kicinski P (2013) Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure. Ann Agric Environ Med 20(4):745–748PubMed
30.
Zurück zum Zitat Hristova K, Cornelissen G, Fedacko J, Singh RB (2014) Echocardiographic study of circadian myocardial function among clinically healthy subjects. World Heart J 6:241–260 Hristova K, Cornelissen G, Fedacko J, Singh RB (2014) Echocardiographic study of circadian myocardial function among clinically healthy subjects. World Heart J 6:241–260
31.
Zurück zum Zitat Singh RB, Gupta S, Dherang P, De Meester F et al (2012) Metabolic syndrome: a brain disease. Can J Physiol Pharmacol 90:1171–1183CrossRefPubMed Singh RB, Gupta S, Dherang P, De Meester F et al (2012) Metabolic syndrome: a brain disease. Can J Physiol Pharmacol 90:1171–1183CrossRefPubMed
32.
Zurück zum Zitat Singh RB, Cornelissen G, Takahashi T, Shastun S et al (2015) Brain-heart interactions and circadian rhythms in chronic heart failure. World Heart J 7:129–142 Singh RB, Cornelissen G, Takahashi T, Shastun S et al (2015) Brain-heart interactions and circadian rhythms in chronic heart failure. World Heart J 7:129–142
36.
Zurück zum Zitat Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE (2004) Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 44:913–918CrossRefPubMed Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE (2004) Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 44:913–918CrossRefPubMed
Metadaten
Titel
Chronic heart failure: a disease of the brain
verfasst von
Ram B. Singh
Krasimira Hristova
Jan Fedacko
Galal El-Kilany
Germaine Cornelissen
Publikationsdatum
20.10.2018
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 2/2019
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-018-9747-3

Weitere Artikel der Ausgabe 2/2019

Heart Failure Reviews 2/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.